Kentaro Enjo
About Kentaro Enjo
Kentaro Enjo is the Medical Affairs Director, Japan at Novocure, with over 20 years of experience in the pharmaceuticals industry, particularly in Oncology Medical Affairs.
Company
Kentaro Enjo is currently working at Novocure as the Medical Affairs Director for Japan. This role is based in Tokyo, Japan and involves on-site responsibilities. Novocure is known for its innovative approach to cancer treatment, particularly with its Tumor Treating Fields (TTFields) technology.
Title
Kentaro Enjo holds the title of Medical Affairs Director, Japan at Novocure. In his role, he is responsible for overseeing medical strategy and execution, coordinating with healthcare professionals, and managing the medical affairs team in Japan.
Education and Expertise
Kentaro Enjo studied Medicine at Tohoku University and achieved a Ph.D. in the field. He also graduated from 東京都立両国高等学校, designated as the 第87回卒業. With over 20 years of experience in the pharmaceuticals industry, he specializes in Oncology Medical Affairs. He is skilled in Key Opinion Leader (KOL) management, Advisory Boards, Evidence Generation, and Publication, and has a strong background in medical strategy planning and people management.
Background
Kentaro Enjo has a comprehensive background in the pharmaceuticals industry, particularly in oncology. He worked at Bayer as the Head of GU&GI Scientific Experts, Medical Affairs Oncology, and at AstraZeneca as Director for Lung Cancer/Tagrisso and Genitourinary Oncology Medical. His earlier career includes significant roles at The Janssen Pharmaceutical Companies of Johnson & Johnson and Astellas Pharma, where he began as a Senior Researcher in Drug Discovery Research. He started his career as a Researcher at Yamanouchi, where he worked for 4 years.
Achievements
Kentaro Enjo holds a Ph.D. in Medicine from Tohoku University and has accrued over 20 years of experience in the pharmaceuticals industry. He has a demonstrated history of working in Oncology Medical Affairs with major pharmaceutical companies like Bayer, AstraZeneca, and The Janssen Pharmaceutical Companies of Johnson & Johnson. His expertise includes KOL management, medical strategy planning, and evidence generation, making him a valuable asset in the field of oncology.